Learn about rheumatoid vasculitis, neutrophilic dermatoses, and other rheumatoid arthritis rashes, their symptoms, and when ...

Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...

Despite advances, there remain gaps in the understanding of and personalized treatment for chronic pain in rheumatology, especially among women.

As GLP-1 RA use soars, experts are worried that patients may not be getting the right nutrients in their diets. How can ...

Hangzhou Sciwind Biosciences Co., a pre-commercial biopharmaceutical company focusing on developing innovative therapies to treat metabolic diseases, today announced a licensing and collaboration ...

Worries that tumor necrosis factor (TNF) inhibitors may exacerbate or even cause lung disease in patients with rheumatoid ...

Cullinan offers promising oncology and autoimmune products, strong financials, and potential for growth, making it a ...

A once-daily dose of ivarmacitinib reduced disease activity and improved function among patients with rheumatoid arthritis ...

The biotech will stop developing two drugs and lay off nearly three-quarters of its staff after its lead therapy wasn’t as potent in early testing as the company expected.

IGM Biosciences (IGMS) is slashing its workforce by 73% and discontinuing development of two of its lead drug candidates in ...

A study published in Cureus has highlighted the high prevalence of anemia among patients with rheumatoid arthritis (RA).

High serum CXCL13 levels are predictive of treatment failure with first-line MTX among patients with early RA.